Xilio Therapeutics (XLO) Other financing activities (2020 - 2026)
Xilio Therapeutics (XLO) posted Other financing activities of $1000.0 for Q1 2026, down 100.0% sequentially from $35.8 million in Q4 2025, and down 80.0% YoY from $5000.0 in Q1 2025.
Xilio Therapeutics (XLO) Other financing activities (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Other financing activities for 7 years, with the latest figure at $1000.0 in Q1 2026.
- Quarterly Other financing activities fell 80.0% year-over-year to $1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.8 million (up 945.9% YoY) and the FY2025 annual result came in at $35.8 million, up 52588.24% from the prior year.
- Other financing activities slipped to $1000.0 in Q1 2026 per XLO's latest filing, from $35.8 million in the prior quarter.
- Over five years, Other financing activities peaked at $35.8 million in Q4 2025 and troughed at -$4.3 million in Q2 2024.
- A 5-year average of $3.3 million and a median of $5000.0 in 2025 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 56755.56% in 2025, down 99.88% in 2025.
- Over 5 years, Other financing activities stood at $16000.0 in 2022, then soared by 1062.5% to $186000.0 in 2023, then sank by 66.13% to $63000.0 in 2024, then soared by 56755.56% to $35.8 million in 2025, then plunged by 100.0% to $1000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $1000.0, $35.8 million, and $4000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35,000.00 |
| Jun 30, 2026 | 35,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | 35.82 Mn |
| Dec 31, 2025 | 35.82 Mn |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Jun 30, 2024 | -4.31 Mn |
| Jun 30, 2024 | -4.31 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Dec 31, 2023 | 186,000.00 |
| Dec 31, 2023 | 186,000.00 |